

STRATEGIC COMMAND REPORT FOR CMT MAJOR INCIDENT COVID-19 RISK REGISTER 20th July 2020

There are 19 risks on the major incident Covid-19 risk register with 2 risks being closed and 1 risk increased in assessed level within this reporting period.







Change in Status

| Risk | Risk Level | Risk Level |
|---|------------|------------|
| | Initial | Current |
| There is a risk that the Laboratories which are involved with Covid 19 | Medium | High |
| testing will not have a robust supply of the reagents required to carry out | (3 x 2) | (3 x 4) |
| testing. This could result in fewer Covid 19 being tested which will impact | | |
| on patient care, bed management and sickness absence levels within | | |
| NHSL. | | |
| | | |
| Increased as availability of reagents continue to be managed nationally | | |
| on a week by week basis making it difficult to predict any potential | | |
| shortfalls in supply. | | |

<u>New Risks</u>

| Opened | Risk | Category | Risk Level |
|--------------|--|----------|------------|
| There are no | new risks identified within this reporting period. | | |

Closed Risks

| Closed | Risk | Category | Risk Level | |
|------------|---|-------------------------|-------------------|--|
| 15/07/2020 | 15/07/2020 There is a risk that we have a shortage or exhaust supplies of PPE for protection against COVID 19. | | Medium (3 x 2) | |
| | Closed: With the exception of Type IIR masks, consumption of PPE is falling in line with the lower prevalence in hospital and in the community. This, coupled with a very stable supply position via NSS National Procurement, the likelihood score can be lowered to 2. We remain on our guard and are maintaining a high degree of vigilance if there was a second wave, but the level of preparedness around PPE supply is much stronger than when the pandemic first started. Type IIR mask usage remains high due to change in guidance, however there is very stable, high volume supply available and to further mitigate, NSS are working with Scottish based suppliers to produce indigenous sources of Type IIR masks | | | |
| 15/07/2020 | There is a risk of lack of availability of chlorine based disinfectant products due to the current supplier of Actichlor disinfectant tablets being out of stock of this product. Closed: NDC have arranged stable alternative substitute products so there is no risk any more. It has also been confirmed by HPS that all of the substitute products are chemically identical and so all conform to the same dilution ratios and drying / contact times as the Actichlor Plus product we were used to so that element of the risk has also been removed | Logistics LOG/PRO/05 | High (3 x 4) | |

Transferred / Integrated Risks

| Transferred | Risk | Category | Risk Level |
|--|------|----------|------------|
| /Integrated | | | |
| No risks transferred or integrated for this reporting period | | | |

Very High Graded Risks (Strategic)

| Category | Reference | Risk |
|----------|------------|---|
| Care | CH/01 | Care home support for patient care and outbreak management |
| Home | | |
| Care | CH/03 | Testing of asymptomatic care home residents & staff creates the |
| Home | | potential for a number of homes to declare an outbreak with impact on |
| | | patient flow from hospital and recovery plans |
| Clinical | CL/PHSC/18 | Impact of overwhelming high volume services as they stand up again, |
| | | regarding physical distancing and footfall eg immunisation and cervical |
| | | smears |
| Finance | FC/01 | Significant financial expenditure & NHSL's ability to sustain recurring |
| | | financial balance for 2020/21 |

High Graded Risks (Tactical)

| Category Of Risk | Reference in Covid Risk Register | Risk Summary |
|---------------------|--|---|
| Clinical | CL/PH/01 | Cessation of opiod substitution therapy |
| Clinical | CL/CRG/09 | Requirement of FFP3 for CPR & potential delays in undertaking CPR |
| Clinical | CL/PHSC/17 | Progression of dental disease in a cohort of young people that can no longer be managed conservatively, and requires urgent surgery with general anaesthesia |
| Clinical | CL/AC/19 | Laboratories potentially will be become overwhelmed as normal NHSL activity starts to resume. This could result in delays to turnaround times which could impact on patient care. |
| Clinical | CL/AC/20 | Supply of Reagents to sustain Covid-19 testing, managing on a week to week basis only |
| Care Home | CH/02 | Capacity to immediately comply with the national testing programme at both local and regional laboratory level, with the potential for non- compliance with the imminent Test, Trace & Isolate (TTI) programme as this is workforce intensive. |
| Public Health | PbH/01 | Lack of national testing strategy for effective staff management |
| Communi cations | COM/05 | Sustainability of care homes due to Covid-19, impacting across H&SCPs' with potential to lead to reputational damage in the eyes of the media, public and service users. |
